CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: A novel approach to separate GvHD from GvL effect

Stem Cells

Volumn 32, Issue 7, 2014, Pages 1890-1903

  Li, Hong ^a   Jiang, Yanming ^b   Jiang, Xiaoxia ^a   Guo, Ximin ^a   Ning, Hongmei ^c   Li, Yuhang ^c   Liao, Li ^c   Yao, Huiyu ^a   Wang, Xiaoyan ^a   Liu, Yuanlin ^a   Zhang, Yi ^a   Chen, Hu ^c   Mao, Ning ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b Second Artillery General Hospital   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Graft versus host disease; Graft versus leukemia effect; Mesenchymal stem cells; Secondary lymphoid organs; Targeted migration

Indexed keywords

CHEMOKINE RECEPTOR CCR7; MESSENGER RNA; RETROVIRUS VECTOR; CCR7 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL ENGINEERING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LYMPHOID ORGAN; MALE; MESENCHYMAL STEM CELL; MOUSE; MOUSE MODEL; MURINAE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; CELL LINE; CHEMOTAXIS; HUMAN; IMMUNOLOGY; LYMPHOID TISSUE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CHEMOTAXIS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HUMANS; IMMUNOMODULATION; KILLER CELLS, NATURAL; LYMPHOID TISSUE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; RECEPTORS, CCR7; T-LYMPHOCYTES;

EID: 84902574385     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1656     Document Type: Article

References (61)

1. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729.
2. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
3. Li H, Guo Z, Jiang X, et al. Mesenchymal stem cells alter migratory property of dendritic cells to delay the development of murine graft-versus-host disease. Stem Cells 2008; 26: 2531-2541.
4. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372.
5. Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
6. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176: 7761-7767.
7. Lin Y, Hogan WJ,. Clinical application of mesenchymal stemcells in the treatment and prevention of graft-versus-host disease. Adv Hematol 2011; 2011: 427863.
8. Martin I, Baldomero H, Tyndall A, et al. A survey on cell and engineered tissue therapies in Europe in 2008. Tissue Eng Part A 2010; 16: 2419-2427.
9. Tyndall A,. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program 2011; 2011: 280-284.
10. Tyndall A, Houssiau FA,. Mesenchymal stem cells in the treatment of autoimmune diseases. Ann Rheum Dis 2010; 69: 1413-1414.
11. Karp JM, Leng Teo GS,. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009; 4: 206-216.
12. Ankrum J, Karp JM,. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203-209.
13. Kang SK, Shin IS, Ko MS, et al. Journey of mesenchymal stem cells for homing: Strategies to enhance efficacy and safety of stemcell therapy. Stem Cells Int 2012; 2012: 342968.
14. Ruddle NH, Akirav EM,. Secondary lymphoid organs: Responding to genetic and environmental cues in ontogeny and the immune response. J Immunol 2009; 183: 2205-2212.
15. Panoskaltsis-Mortari A, Price A, Hermanson JR, et al. In vivo imaging of graft-versus-host-disease in mice. Blood 2004; 103: 3590-3598.
16. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005; 106: 1113-1122.
17. Silva IA, Olkiewicz K, Askew D, et al. Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: A shifting Paradigm for T cell allo-activation. Biol Blood Marrow Transplant 2010; 16: 598-611.
18. Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood 2008; 111: 2919-2928.
19. Coghill JM, Carlson MJ, Panoskaltsis-Mortari A, et al. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. Blood 2010; 115: 4914-4922.
20. Highfill SL, Kelly RM, O'Shaughnessy MJ, et al. Multipotent adult progenitor cells (MAPC) can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 2009; 114: 693-701.
21. Gao J, Dennis JE, Muzic RF, et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12-20.
22. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001.
23. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23-33.
24. von Andrian UH, Mempel TR,. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003; 3: 867-878.
25. Viola A, Contento LV, Molon B,. T cells and their partners: The chemokine dating agency. Trends Immunol 2006; 27: 421-427.
26. Schneider MA, Meingassner JG, Lipp M, et al. CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 2007; 204: 735-745.
27. Shi G, Wu Y, Zhang J, et al. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol 2003; 171: 3407-3414.
28. Brown JA, Bridgman PC,. Disruption of the cytoskeleton during Semaphorin 3A induced growth cone collapse correlates with differences in actin organization and associated binding proteins. Dev Neurobiol 2009; 69: 633-646.
29. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-3239.
30. Reddy P, Teshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2003; 101: 2877-2885.
31. Andoniou CE, van Dommelen SL, Voigt V, et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 2005; 6: 1011-1019.
32. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-3844.
33. Fritz V, Noël D, Bouquet C, et al. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. Stem Cells 2008; 26: 2981-2990.
34. Belema-Bedada F, Uchida S, Martire A, et al. Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell 2008; 2: 566-575.
35. Shurin GV, Tourkova IL, Chatta GS, et al. Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol 2005; 174: 3394-4400.
36. Benvenuti F, Hugues S, Walmsley M, et al. Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science 2004; 305: 1150-1153.
37. Grégoire C, Chasson L, Luci C, et al. The trafficking of natural killer cells. Immunol Rev 2007; 220: 169-182.
38. Aktas E, Kucuksezer UC, Bilgic S, et al. Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009; 254: 149-154.
39. Alter G, Malenfant JM, Altfeld M,. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15-22.
40. Li JM, Giver CR, Lu Y, et al. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy 2009; 1: 599-621.
41. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14: 181-187.
42. Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 2012; 18: 456-462.
43. Liu HB, Liu SB, Li Y, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 2012; 7: e34608.
44. Yang D, Sun S, Wang Z, et al. Stromal cell-derived factor-1 receptor CXCR4-overexpressing bone marrow mesenchymal stem cells accelerate wound healing by migrating into skin injury areas. Cell Reprogram 2013; 15: 206-215.
45. Shi M, Li J, Liao L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Haematologica 2007; 92: 897-904.
46. Yu XF, Lu CL, Liu H, et al. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One 2013; 8: e62703.
47. Chamberlain G, Wright K, Rot A, et al. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: Comparison with human. PLoS One 2008; 3: e2934.
48. Brooke G, Tong H, Levesque JP, et al. Molecular trafficking mechanisms of ultipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 2008; 17: 929-940.
49. Sordi V, Malosio ML, Marchesi F, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419-427.
50. Honczarenko M, Le Y, Swierkowski, M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-1041.
51. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
52. Solchaga LA, Zale EA,. Prostaglandin E2: A putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. Am J Stem Cells 2012; 1: 138-145.
53. Li W, Ren G, Huang Y, et al. Mesenchymal stem cells: A double-edged sword in regulating immune responses. Cell Death Differ 2012; 19: 1505-1513.
54. Prockop DJ, Oh JY,. Medical therapies with adult stem/progenitor cells (MSCs): A backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cellular Biochem 2012; 113: 1460-1469.
55. Sato K, Ozaki K, Oh L, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234.
56. Rezvani AR, Storb RF,. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun 2008; 30: 172-179.
57. Li JM, Giver CR, Lu Y, et al. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy 2009; 1: 599-621.
58. Gottschalk LR, Bray RA, Kaizer H, et al. Two populations of CD56 (Leu-19)+/CD16+ cells in bone marrow transplant recipients. Bone Marrow Transplant 1990; 5: 259-264.
59. Ruggeri L, Mancusi A, Burchielli E, et al. Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy 2006; 8: 554-558.
60. Lundqvist A, McCoy JP, Samsel L, et al. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007; 109: 3603-3606.
61. Abdelrazik H, Spaggiari GM, Chiossone L, et al. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitorycapacity on T- and NK-cell proliferation and function. Eur J Immunol 2011; 41: 3281-3290.